Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMX2OMJ)

Drug Name	Immune globulin DMX2OMJ

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

5 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Virus infection	DISFYSIV	1A24-1D9Z	Approved	[1]
Immunodeficiency	DIS093I0	4A00-4A85	Approved	[1]
Immune System disease	DISPV68Z	4A01-4B41	Approved	[1]
Alzheimer disease	DISF8S70	8A20	Approved	[2]
Bone marrow transplantation	DISYD5IX	QB63.6	Approved	[1]
------------------------------------------------------------------------------------

1 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Nervous system paraneoplastic or autoimmune disorders	DIS5MTRC	8E4A.1	Phase 3	[3]
------------------------------------------------------------------------------------

1 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Pediatric cancer	DISWYLB3	2A00-2F9Z	Phase 2	[4]
------------------------------------------------------------------------------------

1 Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Bacillus anthracis infection	DIS6ZHWU	1G40	Phase 1	[5]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	Clinical pipeline report, company report or official report of Octapharma.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	ClinicalTrials.gov (NCT00110708) Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism. U.S. National Institutes of Health.
5	ClinicalTrials.gov (NCT00448253) Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum. U.S. National Institutes of Health.